Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00007429" target="_blank" >RIV/61989592:15110/08:00007429 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients

Original language description

Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optime

Czech name

Význam testu sensitivity leukemický buněk na inhibitory kináz in vitro při rozhodování o léčbě imatinibem a dasatinibem u nemocných s CML

Czech description

Léčba chronické myeloidní leukémie (CML) rezistentní na imatinib (IM) je obohacena o druhou generaci tyrozinkinázových inhibitorů (TKI), o dasatinib (DAS) a nilotinib. Rozhodnutí o změně terapie lze podpořit testem citlivosti leukemických buněk na jednotlivé TKI in vitro, který umožňuje sledovat míru účinnosti TKI na základě detekce inhibice fosforylace signálních molekul, které jsou substrátem Bcr-Abl tyrozinkinázy.

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2008

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Haematologica: the hematology journal

ISSN

0390-6078

e-ISSN

—

Volume of the periodical

93

Issue of the periodical within the volume

S1

Country of publishing house

IT - ITALY

Number of pages

1

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—